Seres Therapeutics, Inc. Proceeds from Notes Payable
Seres Therapeutics, Inc. (MCRB) reported Proceeds from Notes Payable of $2.00 million for the 9-month period ending 2014-09-30, per its 10-Q filed 2015-11-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2015-11-12
- Seres Therapeutics, Inc. proceeds from notes payable for the quarter ending 2014-09-30 was $500.00K.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month |
|---|---|---|---|
| 2014-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $2.00M 10-Q · filed 2015-11-12 | |
| 2014-06-30 | $1.50M 10-Q · filed 2015-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |